ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1203

Rituximab in Treatment Refractory vs Treatment Naive Anti-Signal Recognition Particle (SRP) Myositis – A Case Series
Abstract Number: 1525

Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment
Abstract Number: 1759

Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
Abstract Number: 0107

Role of Achilles Elastography in Differentiating Patients with Early Psoriatic Arthritis
Abstract Number: 1857

Role of autoantigen-specific reactivity in the pathogenesis of murine interstitial lung disease model with anti-MDA5 antibody mouse model
Abstract Number: 2592

Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis
Abstract Number: 2116

Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
Abstract Number: 0341

Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Abstract Number: LB19

Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Abstract Number: LB09

Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis
Abstract Number: 0765

Rural Access to Physical Therapy for Osteoarthritis Rehabilitation (RAPTOR): A Pilot Feasibility Study
Abstract Number: 2143

Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
Abstract Number: 0987

S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
Abstract Number: 1742

S100B in Childhood-onset Systemic Lupus Erythematosus: Associations with Disease Features, Interferon Levels, and Cognitive Functioning
Abstract Number: 1099

Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].